Pawlikowski Marek
Department of Neuroendocrinology, Medical University of Lodz, Poland.
Folia Histochem Cytobiol. 2010 Sep 30;48(3):394-7. doi: 10.2478/v10042-010-0031-1.
Thirty one pituitary adenomas and 3 samples of peritumoral anterior pituitary tissue were immunostained with an antibody raised against dopamine D2 receptor protein. The positive reactions were found in cell cytoplasm, a subpopulation of cell nuclei and the intratumoral blood vessels walls. As expected, the positive immunostaining was shown in cytoplasm and/or cell nuclei of all examined prolactinomas (7/7). In acromegaly the positive D2 staining occurred in 5/7 samples, in gonadotropinomas in 6/8 and in plurihormonal adenomas 2/4. The lowest expression was observed in corticotropinomas (1/5). These findings corroborate with the well known efficacy of D2 agonists in the treatment of prolactinomas and somatotropinomas, and support the rationale of the therapeutic trials with these compounds in gonadotropinomas. Moreover, the presence of D2 receptors in intratumoral blood vessels walls constitutes the possibility of the anti-angiogenic action of D2 agonists in pituitary adenomas.
用抗多巴胺D2受体蛋白的抗体对31例垂体腺瘤和3份瘤旁垂体前叶组织样本进行免疫染色。在细胞质、部分细胞核及瘤内血管壁中发现阳性反应。正如预期的那样，在所有检测的催乳素瘤（7/7）的细胞质和/或细胞核中均显示出阳性免疫染色。在肢端肥大症中，5/7的样本出现D2阳性染色，在促性腺激素瘤中6/8出现阳性染色，在多激素腺瘤中2/4出现阳性染色。在促肾上腺皮质激素瘤中观察到最低的表达（1/5）。这些发现证实了D2激动剂在治疗催乳素瘤和生长激素瘤方面的众所周知的疗效，并支持了用这些化合物对促性腺激素瘤进行治疗试验的理论基础。此外，瘤内血管壁中存在D2受体构成了D2激动剂在垂体腺瘤中具有抗血管生成作用的可能性。
